50 products were found matching "K04298"!

Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM, IC50 = 1.8 µM), which is the main receptor responsible for ADP-induced platelet aggregation. It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding. Formulations containing ticagrelor...

Farnesyl pyrophosphate is an intermediate in the HMG-CoA reductase pathway and used in the biosynthesis of terpenes, terpenoids, and sterols. It also serves as a donor in post-translational isoprenylation of proteins. FPP has been identified as an antagonist of P2Y12 receptors (IC50 = 45 µM), attenuating platelet...

(±)-Clopidogrel is a racemic mixture of (R)-(-)- clopidogrel and the prodrug form of the active metabolite of clopidogrel (S)-(+)-clopidogrel (Cay-21002).Formal Name: alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetic acid, methyl ester, monohydrochloride. CAS Number: 130209-90-4. Molecular...

2-oxo Clopidogrel is an intermediate metabolite of (±)-clopidogrel (Cay-13657), which consists of R-(-)-clopidogrel and the active isomer S-(+)-clopidogrel (Cay-21002). (S)-(+)-clopidogrel is metabolized by the cytochrome P450 (CYP) isoforms CYP3A4 and CYP3A5 into 2-oxo (S)-(+)-clopidogrel, which is then further...

2-Methylthioadenosine diphosphate (2-MeSADP) is an agonist of purinergic P2Y receptors with EC50s of 5.13 and 0.89 nM for human recombinant P2Y1 and P2Y12 receptors, respectively. It also acts as an agonist at rat P2Y1 and P2Y12 and mouse P2Y13 receptors (EC50s = 0.58, 0.89, and 6.2 nM, respectively). It induces...

Ticagrelor is a platelet aggregation inhibitor. It is a nucleoside analogue and blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. In contrast to the other antiplatelet drugs, ticagrelor has a binding site different from ADP, making it an allosteric antagonist, and the blockage is reversible. The drug...

(S)-(+)-Clopidogrel is a prodrug form of the active metabolite of clopidogrel, which is a purinergic P2Y12 receptor antagonist. It inhibits aggregation of rat platelets induced by ADP, collagen, and thrombin ex vivo (ID50s = 4, 4.8, and 2.9 mg/kg). (S)-(+)-Clopidogrel increases tail bleeding time in rats in a...

Ticlopidine is a thienopyridine P2Y12 receptor antagonist. It inhibits aggregation of human platelets induced by collagen, arachidonic acid (Cay-90010), and ADP (Cay-16778, IC50s = 75, 600, and 1,300 µM, respectively). It also inhibits ADP-induced aggregation of rat platelets and decreases thrombus weight in vivo in...

A platelet aggregation inhibitor capable of inducing apoptosis in various cancer cell lines. Its effects on platelet aggregation may be the result of inhibition of VEGF.

Ticagrelor-d7 is intended for use as an internal standard for the quantification of ticagrelor (Cay-15425) by GC- or LC-MS. Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM, IC50 = 1.8 µM), which is the main receptor responsible for ADP-induced platelet aggregation. It...

Prasugrel is a prodrug form of the platelet purinergic P2Y12 receptor antagonist R-99224. Prasugrel (0.3 and 3 mg/kg) inhibits ex vivo washed platelet aggregation in rat platelet rich-plasma. In vivo, prasugrel prevents thrombus formation (ED50 = 0.68 mg/kg) and increases tail bleeding time in rats. Formulations...

AZD 1283 is an antagonist of the purinergic P2Y12 receptor (IC50 = 25 nM in a GTPgammaS assay in CHO cells). It selectively binds to the P2Y12 receptor (Kd = 11 nM) over more than 100 enzymes, receptors, and ion channels, including the P2Y1, platelet activating factor (PAF), and thromboxane A2 receptors, at 10 µM.,...